Justice-involved individuals are more likely to present with mental health and substance use challenges and use tobacco at high rates. Implementing evidence-based tobacco cessation strategies within correctional systems can reduce health disparities ...
Join APPEAL (Asian Pacific Partners Empowerment, Advocacy, and Leadership) and a panel of experts from the Networking2Save CDC National Networks on Thursday, December 16th at 12 pm ET as we ...
Smoke-free environments in mental health and substance use treatment organizations can reduce tobacco use among these individuals and improve the health of the staff, and yet many mental health and ...
In the U.S., 34% of adults with mental health challenges who use tobacco identify as Black, and 32% identify as Hispanic/Latinx. Understanding this relationship between mental health and substance use ...
Description On February 10, 2022, the U.S. Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) is holding a public webinar titled “FDA’s Rulemaking Process and Planned Tobacco Product ...
Varenicline, an FDA-approved prescription smoking cessation aid, is an effective evidence-based treatment for reducing tobacco use among individuals with mental health and substance use challenges. Join the National Behavioral Health ...
National, state, and local-level data sources are essential to address tobacco-related disparities among individuals with mental health and substance use challenges. But, knowing how to find, understand and apply these ...
Tobacco Use Disorder Integration Office Hours - Monthly Learning Cohort Series Seeking to strengthen partnerships and collaborations with mental health and substance use treatment systems and providers to address tobacco-related ...
